Tag Archive for: Altea Therapeutics

Steven Damon Joins Altea Therapeutics as VP, Business Development

Life Science Partner places drug delivery executive to guide business development

Life Science Partner announced the placement of Steven Damon as vice president, business development at Altea Therapeutics. Hired August 22, 2005, Damon will be responsible for leading activities in product licensing, product pipeline analysis and assessment of competitive products and technologies. 

In particular, he will be responsible for evaluating and concluding agreements for development, manufacturing and marketing of Altea’s products.

“Damon’s knowledge of the drug delivery space, coupled with his repeated success in cultivating strong and productive relationships with potential partners and closing the deal, prepares him well for this key position,” says Cynthia B. Roberts, vice president at Life Science Partner.

As a senior business development executive with DURECT Corporation, Damon was highly successful in assessing market potential, providing due diligence, and term sheet and contract negotiation.  In addition, he handled all market research and market conditioning activities related to the DURECT product pipeline including opinion leader relationships, interviews with patients and physicians, conferences, presentations, pricing and reimbursement planning and product concept planning.  During his tenure, he was also the chairman and president of Absorbable Polymers International, a wholly-owned subsidiary of DURECT. Damon joined the Company as a director of market development responsible for preparing the market for Chronogesic from a commercial development perspective which culminated in a significant deal with Endo Pharmaceuticals.

Previously, Damon spent 13 years with Kimberly Clark proving his versatility in a range of positions. His most recent role as director of mergers and acquisitions for Professional Health Care allowed him to work on two significant medical device acquisitions: Ballard Medical and Safeskin.

Damon spent his early career in the sales and marketing function at Kimberly Clark, starting in Roswell, GA as a sales representative and moving through positions in corporate and district sales before accepting a role as business development manager for Europe based in Düsseldorf.  He was promoted to director of sales for Europe based in London before returning to the US in 1999 in the mergers and acquisitions role.

Learn More About Life Science Partner

Click button below to learn more about how we recruit Chief Executives:

Learn More About Chief Executive Functions
/0 Comments/by

David Enscore to Direct Product Research and Development at Altea Therapeutics

Life Science Partner placement brings a record of innovation to Atlanta-based company

Life Science Partner announces the placement of Dr. David J. Enscore as senior vice president, product research and development with Altea Therapeutics in Atlanta. As an integral part of Altea’s executive leadership, the 20-year industry veteran will direct pharmaceutical and clinical product development while playing an important role in identifying and pursuing strategy. Altea Therapeutics works with the pharmaceutical and biotechnology industries to develop alternatives for medicine and vaccine delivery.

“When we introduced David to Altea, he was very impressed with the company and its microporation technology,” says Life Science Partner Founder and President Thomas H. Callaway. “Because there are so few candidates with David’s qualifications and his unique background suits Altea’s needs perfectly, this is an exceptional placement.”

Enscore comes from Spherics, a Rhode Island-based early phase drug delivery company using bioadhesive polymers and nanoencapsulation to improve the oral bioavailability of therapeutic agents. As vice president of R&D there, he was responsible for all scientific and technical operations the from the company’s inception. Later, Enscore assumed general management responsibilities as well. With Focal, Inc., a medical device company commercializing resorbable surgical sealants and drug delivery platform polymers, he served as vice president and guided all materials-related activities, including all research and development activities related to Focal’s core polymer technologies. During a 16-year career at ALZA Corporation, where he began his career as a chemical engineer, Enscore held the titles of executive director, transdermal product development; director, new product discovery; director, physical sciences; and others. At ALZA, he managed the development of four controlled release pharmaceuticals including the NicoDerm CQ patch. Enscore is an inventor on 24 U.S. patents in drug delivery and medical devices.

Enscore earned both his doctorate in chemical engineering (with a minor in polymer science) and his bachelor’s in chemical engineering at North Carolina State University.

/0 Comments/by